<DOC>
	<DOCNO>NCT03098862</DOCNO>
	<brief_summary>The 2013-2015 Ebola Virus outbreak Western Africa unprecedented size geographic scope . There 28,000 case 11,000 death . During follow outbreak , become evident spectrum disease observe community Ebola treatment unit much broad previously think . In study , aim identify host genetic factor underlie observed variation disease susceptibility , severity , clinical sequela , viral persistence , serological response . We enroll EVD survivor , close contact survivor , EVD healthcare worker , individual receive investigational Ebola vaccine ( population control ) , collect blood sample , HIV/syphilis infection status , demographic , medical history participant . Most subject complete study participation single study visit ; subject HIV/syphilis test do part study return second visit receive HIV/syphilis test result post-test counseling . We genotype participant compare result cohort address study aim . This may provide insight pathogenesis host immunity potentially suggest new method intervention .</brief_summary>
	<brief_title>PREVAIL VI : Identification Host Genetic Factors Underlying Ebola Virus Disease Risk , Mortality , Long-term Sequelae , Viral RNA Persistence , Humoral Immunity , Ebola Vaccine Response</brief_title>
	<detailed_description>The 2013-2015 Ebola Virus outbreak Western Africa unprecedented size geographic scope . There 28,000 case 11,000 death . During follow outbreak , become evident spectrum disease observe community Ebola treatment unit much broad previously think . In study , aim identify host genetic factor underlie observed variation disease susceptibility , severity , clinical sequela , viral persistence , serological response . We enroll EVD survivor , close contact survivor , EVD healthcare worker , individual receive investigational Ebola vaccine ( population control ) , collect blood sample , HIV/syphilis infection status , demographic , medical history participant . Most subject complete study participation single study visit ; subject HIV/syphilis test do part study return second visit receive HIV/syphilis test result post-test counseling . We genotype participant compare result cohort address study aim . This may provide insight pathogenesis host immunity potentially suggest new method intervention .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<criteria>INCLUSION CRITERIA : EVD Survivor : At least 3 year age Positive EBOV serology document RTPCR positive status Willing allow storage biological sample future research purpose Direct EBOV exposure control : At least 3 year age Meets least 1 follow : Household member , family member , friend , careprovider , sexual partner survivor closecontact survivor within 3 week EVD event , history ETU stay treatment EVD CCC hold center Healthcare worker participate treatment EVD patient history ETU stay treatment EVD CCC hold center Participant PREVAIL III enrol closecontact Willing allow storage biological sample future research purpose No known EBOV exposure population control : At least 3 year age . Meets least 1 follow : Enrolled PREVAIL I Enrolled PREVAC/PREVAIL V Willing allow storage biological sample future research purpose EXCLUSION CRITERIA : Severe illness current illness ( e.g . malaria ) require treatment would compromise enrollment study . Individuals exclude due current illness enrol following recovery . Any condition judgement study staff would make volunteer unable participate study . Incapacity provide consent , e.g. , decisional impairment .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 28, 2017</verification_date>
	<keyword>Ebola Virus</keyword>
	<keyword>Genome-Wide Association Study</keyword>
	<keyword>Liberia</keyword>
	<keyword>Ebola Survivors</keyword>
	<keyword>Ebola Contacts</keyword>
</DOC>